NCT07216651 is a clinical trial in Obesity & Overweight, sponsored by Closed Loop Medicine.

Who is sponsoring NCT07216651?

NCT07216651 is sponsored by Closed Loop Medicine.

What condition does NCT07216651 study?

NCT07216651 studies Obesity & Overweight.

Is NCT07216651 still recruiting?

NCT07216651 is currently completed. Last updated 19 March 2026.

Last reviewed 2026-03-19 · How we verify

NCT07216651

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Completed Last updated 19 March 2026

What this trial tests

trial in Obesity & Overweight in 20 participants. Completed in 18 March 2026.

Timeline

23 September 2025

Primary endpoint
27 February 2026

18 March 2026

Quick facts

Lead sponsor	Closed Loop Medicine
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	23 September 2025
Primary completion	27 February 2026
Estimated completion	18 March 2026
Sites	1 location across United States

Conditions studied

Obesity & Overweight — all drugs for Obesity & Overweight →

Sponsor

Closed Loop Medicine — full company profile →

Who can join

18 and older, any sex, with Obesity & Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity & Overweight

Currently open trials in the same condition.

NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07457437 — Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment · NA · recruiting
NCT07396805 — Trial of Food Is Medicine Approaches for Obesity Treatment in Adults With Food Insecurity · NA · recruiting
NCT07349381 — A Food-Effect Study of CX11 in Healthy Participants · Phase 1 · recruiting
NCT07187830 — Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD · recruiting

Other Closed Loop Medicine trials

Trials by the same sponsor.

NCT06372470 — Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in · completed
NCT05093426 — PERSONAL - Sleep In Breast Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07216651 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Closed Loop Medicine
Last refreshed: 19 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07216651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing